Emily Kaiser Maharjan, Assistant Managing Editor

Rafieetary emphasizes the importance of follow-up plans and consistent support to prevent patients from dropping out of treatment, which can negatively impact their prognosis.

Gromacki shares the importance of a dedicated approach to treating keratoconus, highlighting the need for passion, diverse tools, and a committed practice environment to ensure patient success.

Neurotech's ocular implant NT-501 utilizes encapsulated cell therapy to slow the progression of macular telangiectasia type 2 (MacTel). The implant was given a PDUFA goal date of December 17, 2024.

The rabbit model found that the levels of the active metabolites were very comparable, whether or not eyes had received a prior installation of perfluorohexyloctane.

Representatives from CooperVision and the International Agency for the Prevention of Blindness give a preview of what to expect at the "Universal Access to Glasses: Promoting Multisectoral Action" event at this year's World Health Assembly in Geneva, Switzerland.

Nazlee Zebardast, MD, MSc, overviews her 2 presentations from ARVO 2024 that utilized polygenic risk scores to identify patients' genetic risk of developing low risk for different glaucoma subtypes.

Aflibercept-jbvf and aflibercept-yszy are the first interchangeable biosimilars to aflibercept 2 mg that have been approved in the US.

William Reindel, OD, discusses how pupil size affects fit and comfort in multifocal contact lens wearers.

EyeCon chair Kelly K. Nichols, OD, PhD, MPH, FAAO, shares some of her favorite moments throughout her career and what inspires her to continue pushing the industry forward.

Catch up on what happened in optometry during the week of May 6-May 10.

Marjorie Rah, OD, PhD, FAAO, discussed the in-home use test of BioTrue Hydration Plus multipurpose contact lens solution (Bausch + Lomb) on patients who are considering lens dropout.

Michele Andrews, OD, vice president of professional and government affairs for CooperVision, and Terri A. Gossard, OD, MS, member of the AOA board of trustees, sat down with Optometry Times to discuss the goals and tactics of The Myopia Collective.

Andrew S. Morgenstern, OD, FAAO, FNAP, joins Dr. Korik to discuss a newly published study on the incidence of keratoconus among pediatric patients in a Chicago-based study. The pair also discuss the International Keratoconus Academy, and Morgenstern's experience working at Walter Reed Medical Center.

Bryan Wilson, executive director of medical affairs at Genentech, details why Birmingham, Alabama was chosen as the community to study the effects of diabetic eye disease among African Americans in a new manuscript from the ADA and Genentech.

The manuscript, "Breaking Barriers: Partnerships to Improve Diabetic Eye Health in Alabama," highlights the burden of diabetic eye disease in Alabama, as well as strategies that target racial health disparities within that population.

Jill Saxon, OD, FAAO, chats about eye health safety for the upcoming total solar eclipse on April 8, 2024, and how Bausch + Lomb is celebrating the celestial event.

Davis Corley, CEO of Neurolens, outlines the importance a new study that show statistically significant improvement of headaches with the use of Neurolens.

One of the 15 clinics Miriam Korik, OD, works at is an optical boutique. She shares her expertise on exam personalization and how to realize these tweaks as sales.

March 23 is World Optometry Day, and we asked members of the optometric community one question: How does optometry make the world a better place?

The new model features stray light shielding, active micro-lens optics, improved power efficiency, and a scalable platform.

Dr Brianna Rhue, OD, FAAO, FSLS details her upcoming presentation "Cutting Out Surgery for the Management of Refractive Error," where she will detail the underutilization of orthokeratology during Vision Expo East 2024 later this week.

Professor and chief of low vision rehabilitation service Patrick D. Yoshinaga, OD, MPH, FAAO, chats with Dr Korik about assistive tech, AI, and accessibility for patients with low vision.

Marc R Bloomenstein, OD, FAAO, chats with Optometry Times on the benefits of using Vevye to treat dry eye disease, when to prescribe, and how to distinguish quality candidates.

The approval marks the first new steroid on the ophthalmic market in more than 15 years.

Eric Fazio, OD, sits down with Optometry Times to weigh the pros and cons of EVO ICLs and LASIK and the role comanagement plays in the decision.

Barry Eiden, OD, FAAO, FSLS, sits down with Optometry Times to highlight the importance of staying up-to-date with technology in the development of treatment and diagnosis of keratoconus and what's to come at this year's IKA Keratoconus Symposium in May.

Second annual meeting builds upon firm foundation to enhance education.

Welcome to the You and Eye podcast. We're kicking things off with a little bit of background on our host, Miriam Korik, OD. She chats about her journey as an optometrist and where she sees herself—and this podcast—going.

Andrew S. Morgenstern, OD, FAAO, FNAP sits down with Optometry Times to reiterate under-utilized diagnostic tools for keratoconus and the planning of this year's International Keratoconus Academy Keratoconus Symposium, running from May 18-19 in Bethesda, Maryland.

Diffusion Optics Technology (DOT) spectacle lenses are intended to slow myopia progression in children via contrast management mechanism of action.